Onpode
Cover art for An experimental pill paired with chemotherapy shrank tumors in most advanced pancreatic cancer patients—early phase results at Barcelona conference

An experimental pill paired with chemotherapy shrank tumors in most advanced pancreatic cancer patients—early phase results at Barcelona conference

November 22, 2026 · 8 min

Hugo Vance & Lila Soto

Daraxonrasib, an experimental pill targeting KRAS, shrank tumors in 60.7% of 61 first-line metastatic pancreatic cancer patients when added to standard chemotherapy, with a median progression-free survival of 12.8 months. The trial has no control arm, so the randomized RASolute 303 trial is needed to confirm whether the drug itself drives the benefit.

Updated Phase 1/2 results from the RMC-GI-102 open-label study of daraxonrasib (brand name Rasonque), developed by Revolution Medicines, were presented on November 20, 2026, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain. The presentation was delivered by lead investigator Wungki Park of Memorial Sloan Kettering Cancer Center.

0:008:14
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

Pancreatic cancer has one of the cruelest statistics in oncology: a five-year survival rate of roughly 3% for metastatic disease. It also has a molecular villain that researchers identified in the early 1980s and spent four decades calling undruggable — a mutant protein named KRAS that acts like a gas pedal stuck to the floor in more than 90% of tumors. This episode looks hard at what happened on November 20th in Barcelona, when early-phase data for daraxonrasib, a pill designed to jam that pedal, were presented at the 38th EORTC-NCI-AACR Symposium. Sixty-one first-line metastatic patients. A 60.7% confirmed response rate. Median progression-free survival of 12.8 months. Five complete responses — five scans with nothing left to measure. The numbers are striking. The episode doesn't let them off easy. There's no control arm, no published overall survival figure, and a long history of promising Phase 2 results in this disease that didn't survive Phase 3. The comparison to a 2013 chemotherapy trial looks enormous on paper, but the episode explains exactly why that comparison is not definitive. What moves the needle from early signal to real advance is a randomized trial called RASolute 303, now underway, pitting the combination against chemotherapy alone. The episode holds the excitement and the uncertainty in the same room — and ends on a question worth sitting with: if the pill works, does the infusion chair go?

Frequently asked

What response rate did daraxonrasib show in metastatic pancreatic cancer?

Daraxonrasib combined with gemcitabine and nab-paclitaxel produced a confirmed objective response rate of 60.7% — 37 of 61 first-line metastatic pancreatic cancer patients had measurable tumor shrinkage confirmed on a follow-up scan. Five patients, 8.2%, achieved a complete response with no tumor detectable on imaging.

How does daraxonrasib work against pancreatic cancer?

Daraxonrasib targets KRAS, a mutation present in over 90% of pancreatic tumors. The drug works by jamming the KRAS signaling pathway — described as wedging under a gas pedal stuck to the floor — directly blocking the driver mutation that makes most pancreatic cancers grow.

What was the progression-free survival for daraxonrasib plus chemotherapy in pancreatic cancer?

In trial RMC-GI-102, daraxonrasib plus gemcitabine and nab-paclitaxel achieved a median progression-free survival of 12.8 months, with an interval of 10.8 to 18.4 months. Twelve-month overall survival was 76.6%. Median overall survival had not been reported at the data cutoff of September 28th.

Where was the daraxonrasib pancreatic cancer data first presented?

Updated daraxonrasib trial data was presented on November 20th by Wungki Park of Memorial Sloan Kettering at the 38th EORTC-NCI-AACR Symposium in Barcelona, as late-breaking oral abstract 8LBA. Revolution Medicines issued its press release the day before the presentation.

Is daraxonrasib proven to beat standard chemotherapy for pancreatic cancer?

Daraxonrasib has not yet been proven superior to standard chemotherapy alone. Trial RMC-GI-102 had no control arm, so all 61 patients received the combination. The randomized RASolute 303 trial, comparing daraxonrasib plus chemotherapy against chemotherapy alone, is the test needed to confirm the drug's added benefit.

Grounded in 7 sources
90% Of Patients Saw Their Pancreatic Cancer Controlled With This New Treatment ↗ · health.yahoo.com
This Experimental Drug Could Be a Game Changer for Pancreatic Cancer ↗ · gizmodo.com
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | Training | ASEM ↗ · asem-medical.com
Rasonque Posts 12.8 Month PFS in First Line Pancreatic Cancer ↗ · biomednexus.com
Erasca data add to pressure facing Revolution’s breakthrough cancer drug | BioPharma Dive ↗ · biopharmadive.com
Daraxonrasib's Frontline Signal Has to Prove the Chemo Still Belongs ↗ · bioreview.com
Daraxonrasib + Chemo in Pancreatic Cancer: 60.7% Response ↗ · drozdogan.com
Read transcript

Hugo Vance: Lila, good to see you again. You've got the look of someone with a story, so out with it.

Lila Soto: Oh, I do. Two scenes, same Tuesday. In one, a person is in an infusion chair for hours getting gemcitabine and nab-paclitaxel. In the other, a 200 mg pill, daraxonrasib, sits by a coffee mug. It's ten seconds. Which one feels like hope?

Hugo Vance: The pill. But I can't yet say why a pill should work at all.

Lila Soto: Right — and that's the clever bit. KRAS drives over 90% of pancreatic tumors. Imagine a gas pedal stuck to the floor, and this pill jams the pedal while it's pressed down.

Hugo Vance: Ah. Forty years of calling it undruggable, and the answer is a wedge under the pedal.

Lila Soto: Mm, roughly. Revolution Medicines built it, and I keep wondering what it actually did in the trial.

Hugo Vance: Well, here is what it did. On November 20th, in Barcelona, Wungki Park of Memorial Sloan Kettering stood up at the 38th EORTC-NCI-AACR Symposium, a late-breaking oral abstract, number 8LBA. The trial is RMC-GI-102. Sixty-one first-line metastatic patients, daraxonrasib plus gemcitabine and nab-paclitaxel, data cutoff September 28th, median follow-up 18.3 months.

Lila Soto: Oh, and the headline number was 60.7%. Mm, but what does that mean for an actual person? Sixty-one people, so that's... 37 of them?

Hugo Vance: Thirty-seven, yes. Confirmed objective response. Their tumors measurably shrank, and the shrinkage was confirmed on a later scan.

Lila Soto: Okay, but there's a bigger one. 90.2% disease control. That sounds like nine in ten got better.

Hugo Vance: Now, that is the misreading I'd head off. Disease control adds the people whose tumors simply held still. Fifty-five of 61. So 37 shrank, and about eighteen more stabilized. Stable is good in this disease, but it is not shrinkage.

Lila Soto: Huh. And the earlier look, with 40 patients, was 58%?

Hugo Vance: Yes, 58% with one complete response. Then 60.7% at 61 patients. Well, a figure that barely moves as you add twenty-one people is steadier than one that swings. Yes, I'd call that reassuring, though not proof.

Hugo Vance: And now my small surprise. The complete response rate, 8.2%. It sounds like a statistic. It's five people. Five scans with nothing left to measure. Median PFS is 12.8 months, interval 10.8 to 18.4, and 12-month survival is 76.6%. But median overall survival, not reported.

Lila Soto: Five. Oh wow. That's a dinner table, not a percentage.

Hugo Vance: But five people at a dinner table is exactly where I'd slow down. Those five scans tell us nothing about what caused them. There is no control arm. Sixty-one patients, everyone got the combination, and nobody got chemotherapy alone.

Lila Soto: Mm. So how do you hold the excitement and the uncertainty at once? Because the Science Media Centre expert said it almost flatly. Comparisons with historical chemotherapy results are therefore not definitive.

Hugo Vance: Well, you hold them by naming the comparison. The pivotal 2013 gemcitabine plus nab-paclitaxel trial had a median PFS of about 5.5 months. Against 12.8, it looks enormous. But different patients, a different era, different scanning habits. You see the problem.

Lila Soto: Huh. So what faded before? Pancreatic cancer has so many false dawns.

Hugo Vance: PEGPH20. It looked promising in Phase 2, and it failed. Now, I'd have said thirty years ago that early pancreatic data almost never survive Phase 3. This signal is larger, and the mechanism is credible. Yet I can't say the drug itself did the work.

Lila Soto: Oh, can I add my small surprise? The dates. Revolution Medicines put out the press release November 19th, Wungki Park spoke on the 20th, and some sources say the 21st. Not yet peer reviewed, company-funded, and already it's "the story."

Hugo Vance: Mm. Hold the Mayo Clinic Press line loosely too, then. "Doubled overall survival," second-line. I can't corroborate it anywhere. And the human cost of that missing control arm, one particular woman's Tuesday, is the part that makes this harder.

Lila Soto: But wait, that Tuesday you mentioned. I keep trying to picture it. Someone sitting across from her oncologist, and the trial is RASolute 303, daraxonrasib plus chemotherapy against chemotherapy alone. What does she actually hear?

Hugo Vance: She is sixty-four, a retired schoolteacher, liver metastases, newly diagnosed. The oncologist explains randomization. She might get the pill and the infusion. She might get the infusion alone. A coin flip, on a drug nobody has yet shown beats the chemotherapy she'd get anyway.

Lila Soto: Mm. And the number sitting under that room is roughly 3%. Five-year survival, metastatic pancreatic ductal adenocarcinoma. So I wonder, can caution be too cautious here?

Hugo Vance: Well, yes. It can. Caution becomes a posture, you see, a way of never being wrong. I said PEGPH20 failed after a good Phase 2, and it did. But this signal is larger than any of those, and the mechanism is credible.

Lila Soto: Credible how? Because Ryan Augustin at Mayo said, and I wrote it down, "It's been called undruggable for decades… really revolutionary."

Hugo Vance: Credible because it hits KRAS directly. And the Science Media Centre put it carefully: if confirmed, "one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years." Note the "if."

Lila Soto: Oh, that "if" is her whole Tuesday. So what would move you from the if to the yes?

Hugo Vance: A survival advantage in RASolute 303. Over chemotherapy alone. And benefit that lasts. The median duration of response is 11.1 months, just under the 12.8 months of PFS. I'd want to see the tail of that curve reach well past it.

Lila Soto: Past eleven months. That's one school year and then some.

Hugo Vance: One school year and then some, yes. And RASolute 303 is the test that settles it, whether daraxonrasib plus chemotherapy beats chemotherapy alone. If it does, there's a second question behind it: which patients need the chemotherapy backbone at all.

Lila Soto: Oh. So the infusion chair might be the thing that goes. Not the pill.

Hugo Vance: Perhaps for some. Nobody knows yet. KRAS was identified as an oncogene in the early 1980s, and for about forty years we called it undruggable. Well, words like that take a long time to retire properly.

Lila Soto: Mm. And I think that's where I've landed. Still the pill next to the coffee mug, ten seconds. I just can't say yet whether it's hope or only the look of it. The answer's coming, though.